AI summary by TwinMind
Why useless decongestants are still for sale
Vox
9m 52s
Background: Decongestant Market Evolution
- Sudafed vs Sudafed PE comparison: pseudoephedrine vs phenylephrine
- Phenylephrine vastly outsells pseudoephedrine today despite ineffectiveness
- Personal experience: daily phenylephrine use with no relief
FDA's Historical Regulatory Framework (1962-1990s)
- 1962: FDA charged with reviewing safety/effectiveness of drugs
- Started with prescription drugs first due to higher concern
- 1972: OTC review began for massive shelf (100,000-500,000 products)
- Too many products for thorough review
- Grandfathered existing ingredients if "generally recognized as safe and effective"
- 1976: Panel recommended three nasal decongestants:
- Phenylephrine (red - ineffective)
- Pseudoephedrine (blue - effective)
- Phenylpropanolamine (grey - later removed)
- 1990s: List further codified
- Pseudoephedrine became dominant OTC decongestant through 80s-90s
The Methamphetamine Problem (2005)
- Pseudoephedrine essential ingredient for making methamphetamine
- 2005: Combat Methamphetamine Act (attached to Patriot Act)
- Pseudoephedrine moved behind pharmacy counter
- Required ID verification and purchase limits
- Phenylpropanolamine removed by 2000 due to hemorrhagic stroke risk
- Phenylephrine left alone on shelves
- Companies like Pfizer created "PE" versions (Sudafed PE)
- Phenylephrine sales began exceeding pseudoephedrine
Early Evidence of Ineffectiveness (2006)
- 2006 headline: "Sudafed's replacement no winner"
- Florida researcher received calls about phenylephrine not working
- Study found: "oral phenylephrine is ineffective as nasal decongestant but safe"
- Most effectiveness studies came from single lab: Elizabeth Biochemical
- Congressional support from Representative Henry Waxman
- Further studies confirmed ineffectiveness
Regulatory Obstacles and Delays (2006-2023)
- Dr. Janet Woodcock (FDA Center for Drug Evaluation): burdensome multi-step rulemaking process
- Process "frozen in 1972 and before"
- No innovation pathway for OTC drugs
- Significantly smaller funding for OTC division vs prescription drugs
- 2020 CARES Act: provided more tools and resources for OTC division
- Made drug amendments slightly easier
2023 FDA Panel Review
- Advisory panel reviewed new studies with clear data
- Charts showed:
- Nasal congestion decreased with pseudoephedrine
- No improvement with phenylephrine (similar to placebo)
- Panel votes against phenylephrine effectiveness
- Panel mystified by phenylephrine market dominance
Panel Member Reactions
- "Amazing amount of dollars spent on something with no efficacy"
- Medical professionals unaware of limited data despite training
- "Drug companies made billions off this medication for years"
- Concerns about changing pharmacy aisle layouts
- Unanimous recommendation against effectiveness
Current Status and Producer Note
- FDA panel vote is recommendation requiring FDA implementation
- Producer Phil Edwards explains Vox's free journalism mission
- Request for contributions at vox.com/give-now
- Recurring contributors get newsletters and behind-the-scenes access
